Flemming Winther Bach

Ultramicronized Palmitoylethanolamide (PEA) in spinal cord injury neuropathic pain: a randomized controlled trial

Publikation: KonferencebidragPosterForskning

Standard

Ultramicronized Palmitoylethanolamide (PEA) in spinal cord injury neuropathic pain: a randomized controlled trial. / Andresen, Sven Robert; Bing, Jette; Hansen, Rikke Bod Middelhede; Biering-Sørensen, Fin; Johansen, Inger Lauge; Hagen, Ellen Merete; Rice, Andrew; Nielsen, Jørgen Feldbæk; Bach, Flemming Winther; Finnerup, Nanna Brix.

2015.

Publikation: KonferencebidragPosterForskning

Harvard

APA

CBE

MLA

Vancouver

Author

Andresen, Sven Robert ; Bing, Jette ; Hansen, Rikke Bod Middelhede ; Biering-Sørensen, Fin ; Johansen, Inger Lauge ; Hagen, Ellen Merete ; Rice, Andrew ; Nielsen, Jørgen Feldbæk ; Bach, Flemming Winther ; Finnerup, Nanna Brix. / Ultramicronized Palmitoylethanolamide (PEA) in spinal cord injury neuropathic pain: a randomized controlled trial. 1 s.

Bibtex

@conference{b7149778d9fa4c9da91f6722a763f4cd,
title = "Ultramicronized Palmitoylethanolamide (PEA) in spinal cord injury neuropathic pain: a randomized controlled trial",
abstract = "Introduction Neuropathic pain and spasticity after spinal cord injury (SCI) represent significant problems. Palmitoylethanolamide (PEA) is a fatty acid that isproduced in many cells in the body, and it is thought to potentiate endocannabinoids. PEA is suggested to reduce pain and inflammation but RCT arelacking. Normast is a medical supplement which contains PEA approved for use in Denmark. The primary aim was to investigate the effect of Normaston neuropathic pain, and secondary to study the effect of Normast on spasticity and psychological functioning in patients with spinal cord injury.Methods A randomized, double-blind, placebo-controlled parallel multicenter study. Study population of at least 66 patients must complete the 12 week trial.Questionnaires regarding neuropathic pain, spasticity, insomnia, anxiety and depression are completed before and after treatment. A numeric ratingscale for pain intensity (0-10 point) is used to measure primary outcome.Results Presently, 66 of 68 patients (74{\%} male) have completed the trial. Of those included, 5{\%} have complete tetraplegia, 39{\%} incomplete tetraplegia,29{\%} complete paraplegia and 27{\%} incomplete paraplegia. Average age at inclusion is 55.3 (±9.5) years and average time since injury is 8.8 (±8.9)years. Causes of injury are 31{\%} transport, 27{\%} fall, 21{\%} non-traumatic SCI, 14{\%} other traumatic cause and 7{\%} sports injuries. No major side effectshave been reported. Further results will be presented at the meeting",
author = "Andresen, {Sven Robert} and Jette Bing and Hansen, {Rikke Bod Middelhede} and Fin Biering-S{\o}rensen and Johansen, {Inger Lauge} and Hagen, {Ellen Merete} and Andrew Rice and Nielsen, {J{\o}rgen Feldb{\ae}k} and Bach, {Flemming Winther} and Finnerup, {Nanna Brix}",
year = "2015",
month = "9",
day = "9",
language = "English",

}

RIS

TY - CONF

T1 - Ultramicronized Palmitoylethanolamide (PEA) in spinal cord injury neuropathic pain: a randomized controlled trial

AU - Andresen, Sven Robert

AU - Bing, Jette

AU - Hansen, Rikke Bod Middelhede

AU - Biering-Sørensen, Fin

AU - Johansen, Inger Lauge

AU - Hagen, Ellen Merete

AU - Rice, Andrew

AU - Nielsen, Jørgen Feldbæk

AU - Bach, Flemming Winther

AU - Finnerup, Nanna Brix

PY - 2015/9/9

Y1 - 2015/9/9

N2 - Introduction Neuropathic pain and spasticity after spinal cord injury (SCI) represent significant problems. Palmitoylethanolamide (PEA) is a fatty acid that isproduced in many cells in the body, and it is thought to potentiate endocannabinoids. PEA is suggested to reduce pain and inflammation but RCT arelacking. Normast is a medical supplement which contains PEA approved for use in Denmark. The primary aim was to investigate the effect of Normaston neuropathic pain, and secondary to study the effect of Normast on spasticity and psychological functioning in patients with spinal cord injury.Methods A randomized, double-blind, placebo-controlled parallel multicenter study. Study population of at least 66 patients must complete the 12 week trial.Questionnaires regarding neuropathic pain, spasticity, insomnia, anxiety and depression are completed before and after treatment. A numeric ratingscale for pain intensity (0-10 point) is used to measure primary outcome.Results Presently, 66 of 68 patients (74% male) have completed the trial. Of those included, 5% have complete tetraplegia, 39% incomplete tetraplegia,29% complete paraplegia and 27% incomplete paraplegia. Average age at inclusion is 55.3 (±9.5) years and average time since injury is 8.8 (±8.9)years. Causes of injury are 31% transport, 27% fall, 21% non-traumatic SCI, 14% other traumatic cause and 7% sports injuries. No major side effectshave been reported. Further results will be presented at the meeting

AB - Introduction Neuropathic pain and spasticity after spinal cord injury (SCI) represent significant problems. Palmitoylethanolamide (PEA) is a fatty acid that isproduced in many cells in the body, and it is thought to potentiate endocannabinoids. PEA is suggested to reduce pain and inflammation but RCT arelacking. Normast is a medical supplement which contains PEA approved for use in Denmark. The primary aim was to investigate the effect of Normaston neuropathic pain, and secondary to study the effect of Normast on spasticity and psychological functioning in patients with spinal cord injury.Methods A randomized, double-blind, placebo-controlled parallel multicenter study. Study population of at least 66 patients must complete the 12 week trial.Questionnaires regarding neuropathic pain, spasticity, insomnia, anxiety and depression are completed before and after treatment. A numeric ratingscale for pain intensity (0-10 point) is used to measure primary outcome.Results Presently, 66 of 68 patients (74% male) have completed the trial. Of those included, 5% have complete tetraplegia, 39% incomplete tetraplegia,29% complete paraplegia and 27% incomplete paraplegia. Average age at inclusion is 55.3 (±9.5) years and average time since injury is 8.8 (±8.9)years. Causes of injury are 31% transport, 27% fall, 21% non-traumatic SCI, 14% other traumatic cause and 7% sports injuries. No major side effectshave been reported. Further results will be presented at the meeting

M3 - Poster

ER -